Summary.-The effectiveness of maltose tetrapalmitate (MTP) as an antitumour immune adjuvant was verified by its comparison with other known immunopotentiators, namely BCG, Corynebacterium parvum, levamisole and pyran copolymer. Copenhagen x Fisher 344/CRBL F1 hybrid male rats inoculated s.c. with the Dunning R3327A prostatic adenocarcinoma were used as the test system. All animals treated with immunoadjuvants showed a delay in tumour appearance and inhibition of early tumour growth. MTP was found to be the most effective, followed by levamisole, BCG, pyran copolymer and C. parvum in order of decreasing efficacy. Intratumoral treatment of small or large s.c. tumours with BCG, MTP and C. parvum was ineffective in our cases. However, this treatment was effective with MTP and BCG if they were used against a differentiated form of R3327 tumour. MTP and levamisole were found to be equally effective when given orally in drinking water.
CANCER THERAPY with immunoadjuvants has come to be recognized as a useful adjunct to conventional modes of cancer treatment (Hersh et al., 1977) . At present, clinical use of immunoadjuvants is limited to Bacillus Calmette-Guerin BCG), BCG-derived products, heat-killed C. parvum, and levamisole. In addition, pyran copolymer (Weissman et al., 1977) , glucan (Chihara et al., 1970) and synthetic polynucleotides (Came & Moore, 1971) have shown promise in animal experiments as immuno-potentiators and as antitumour agents. On the other hand, some of these products show some toxicity in animals and in humans and occasionally cause tumour enhancement (Berd et al., 1976; Hersh et al., 1977; Mohr et al., 1976) . Yarkoni & Rapp (1979) have described use of BCG cell walls plus trehalose dimycolate in mineral oil and Tween in the cures of guinea-pigs bearing small intradermal (i.d.) hepatoma Line 10 tumour, and regression of regional lymph node metastasis. However, recent experiments of Ribi et al. (1979) suggest caution in the use of such mixtures, because of accompanying toxicity.
We have recently described the synthesis, immunopotentiating capabilities and antitumour activity of a simple glycolipid, maltose tetrapalmitate (Nigam et al., 1978) . This substance is nonimmunogenic, and was shown to be nontoxic by several criteria. Its degradation products (glucose, maltose and palmitic acid) are normal constituents of animal tissues. Since maltose tetrapalmitate (MTP) appeared to be a suitable compound for clinical use as a substitute for the currently used bacterial products and chemically derived agents, we were interested to know whether its antitumour potential was equivalent to that of the available immunoadjuvants. We have therefore compared the antitumour activities of BCG, C. parvum, levamisole, pyran copolymer and MTP against a single animal tumour model. The tumour chosen was Dunning R3327 transplantable rat prostatic adenocarcinoma, because of the similarity of its growth rate, differentiation and biochemical behaviour in vivo to that of human prostatic cancer (Symoens et al., 1978) . It was transplanted s.c. rather than i.d., because our intention was to see whether immunoadjuvants would prevent acceptance and growth of the transplant at an observable site, where it effectively vascularizes and proliferates, and where it has been conventionally transplanted for several years. J.d. tumours are indeed rare, and they offer little similarity to most human cancers (Carbone, 1977) . Comparisons were also made between MTP and BCG given intratumorally and between MTP and levamisole given orally.
Considering that a pressing problem in human cancer treatment is tumour recurrence and metastasis after surgical removal of operable cancer, we were also interested in determining whether MTP immunotherapy after surgery would provide an inhibition of or delay in local tumour recurrence and an inhibition of its subsequent growth. This paper describes these results in two non-metastatic animal tumour models. (Woodruff et al., 1974) ; levamisole was injected, after being diluted in water, at a dose of 12-5 mg/kg body wt (IFaanes et al., 1977; Hawrylko, 1973; Woodruff et al., 1974) . Tumour size was determined at intervals of 4-5 days by measurement of the long and short axes of the tumour and expressed as their product. BCG and MTP were also used in dose-response studies. Intratumoral injection of immunoadjuvant w,as carried out with the above doses when the s.c. tumours were large (2-3 cm in diameter) or small (0-2-0-5 cm in diameter).
Oral treatment of rats with levamisole and MTP was carried out via the daily water intake (Fisher et al., 1978) . Levamisole was given to a total dose of 12-5 mg/rat and MTP, 10 jig/rat. The drinking water contained 15-6 mg levamisole or 50 jig MTP per 500 ml tap water for each group.
The comparative values were extrapolated in relation to tumour size by t test. Differences between groups were considered significant if P for the comparison was 0 05 or less.
Tumour development, surgical excision and MTP treatment.-Fisher rats and Syrian hamsters were inoculated s.c. in the back with 107 MAC and C12TSV5S cells respectively. The animals were allowed food and water ad libitum. When the tumours had grown to -0-5-2 cm in diameter (except Exp. No. 4 in the Table, where the tumours were 2-3 cm in diameter) they were surgically excised under aseptic condition using sodium pentobarbital (Abbott Laboratories Ltd, Montreal, Canada) anaesthesia. Using the undiluted stock solution (50 mg/ml), the rats were injected at a level of 7-5 mg/100 g body wt (0 15 ml) and the hamsters received 10 mg/100 g body wt (0-2 ml). The wounds were closed with 9mm Clay Adams wound clips. When the animals had recovered from anaesthesia, they were randomly divided into two groups: one group was given 0-2 ml of 0-9%o NaCl s.c. in the flank opposite to the tumour site, and the other group similarly received 0-2 ml of MTP solution (10 ,ug) . This treatment was given 3 times a week and continued for about 3 weeks. Tumour reappearance at the original site and the size of any tumours that developed were recorded every 2-3 days by measurement of the long and short axes of the tumour and expressed as their product. When the effects of pre-and postoperative MTP treatment were to be determined, MTP was given 7 and 3 days before tumour excision, and this treatment was continued thrice w%eekly thereafter as described above. Fig. 1 shows the combined results of 3 experiments on the efficacy of various immunoadjuvants. (One of these experiments did not include C. parvum and pyran copolymer.) The criteria used to compare antitumour activity were: the percentage of tumour takes at 4 intervals (Days 7, 11, 15 and 20) and the average size of tumours that developed (Fig. 1 
RESULTS

Antiturnour activity of immunoadjuvants
DISCUSSION
When a new antitumour immunoadjuvant becomes available, it has to be compared with currently used immunotherapeutic agents against cancer. The development of MTP in our laboratory as a potential antitumour immunoadjuvant thus made the present study necessary. In addition, it was felt that if MTP proved to be comparable or superior to other immunoadjuvants, it should be tested in a simulated human-cancer model in which immunotherapy is used for the prevention of tumour recurrence and for slowing the growth of the recurring tumour after cytoreductive therapy.
The results from the comparative study, and in the R3327 animal tumour model, indicated that MTP was superior to other adjuvants during the early period (up to Day 15), since both the incidence and growth rate of tumours were significantly reduced by MTP treatment. By these criteria, the adjuvants could be graded in their order of effectiveness as follows: MTP, levamisole, BCG, pyran copolymer and C. parvum. After Day 15, the antitumour effect of immunoadjuvants dropped and tumour growth rate increased. However, even on Day 20, when most of the immunoadjuvants had lost their effectiveness (and tumour size was the same in untreated and treated animals), MTP-treated animals had an average tumour size still significantly lower than that of the controls.
In several previous attempts to obtain an antitumour effect from MTP given by intratumoral inoculation in several tumour-host models carrying poorly differentiated transplantable tumours, we had no success. When MTP was compared with C. parvum and BCG with small (0 3-0-5cm diameter) and large (1.0-3 0cm diameter) fast-growing R3327A tumour, the 3 products all failed to produce either a regression or a decrease in Another comparison of MTP with P copolymer, BCG and C. parvum was made when 106 R3327A tumour cells admixed with optimum doses of immunoadjuvants in mineral oil were inoculated s.c. into rats. MTP and C. parvum delayed but did not prevent tumour takes, whereas BCG and P copolymer were totally ineffective (results not described in text). This observation indicates that the number of injected R3327A cells (106) was high and that they multiplied rapidly before the immunoadjuvants could deliver an effective modulating signal to the immune system to destroy their increasing numbers. The ability of MTP to control growth without preventing tumour take indicates that this substance does indeed control tumour proliferative capacity, and its action is comparable to that of C. parvum and superior to those of BCG and P copolymer. The last comparison was of the role of oral MTP and levamisole in preventing tumour take and tumour growth. Both substances were equally effective in delaying tumour appearance and reducing tumour growth. The advantage of oral MTP is noteworthy because of its convenient administration as a substitute for levamisole, which is normally given orally and has some toxicity. It is interesting to note that muramyl dipeptide (MDP), which is a known immunoadjuvant in cell walls of bacteria, also enhances immune reactions when given to animals by the oral route (Chedid et al., 1978) .
These comparisons indicate that MTP provides equal or superior antitumour activity when it is given s.c. to animals, and is also effective when given by those routes which are favoured for an immunoadjuvant: viz. intralesional BCG and oral levamisole.
Comparisons between adjuvants other than MTP have been reported in several studies. Mathe et al. (1973) compared the immunoprophylactic effects of BCG, MER, C. parvum, poly I-poly C and poly A-poly U administration before tumour (L 1210 and Lewis lung tumour) inoculation, and observed no significant increases in survival times. Proctor et al. (1977) found that BCG, levamisole and glucan administered in 4 dose levels (2, 5, 25 and 250 pg/mouse) i.p. as well as i.d. to 4 limbs were ineffective in delaying s.c. B16 melanoma. Bruley-Rosset et al. (1978) compared the immunomodulating effects of BCG and levamisole, and found that in young mice a single BCG injection activated cellmediated and humoral immunities, as well as inducing suppressor cells, whereas levamisole had no effect. In aged mice, BCG inhibited humoral response and generated suppressor cells, whereas levamisole restored humoral immune response and failed to induce suppressor cells. This finding could explain the superiority of levamisole over BCG in our experiments.
The effectiveness of MTP immunotherapy in cancer treatment was appreciated when it was administered after removal of tumour and the recurrence and growth rates of the tumour were measured. The tumours used were MAC and C12TSV5S, one of which recurs locally in all animals after surgery, whereas the other one, which is more immunogenic, recurs locally in 40-50% of the animals.
In the first series of two experiments in Fisher rats bearing MAC tumour, MTP treatment after tumour excision prevented regrow thin 50% of the animals.
The tumours in this case were excised at an early stage of development (<1 cm diameter). Large tumours upon excision either left behind more tumour cells or the animals were more immunosuppressed, so that MTP could not prevent tumour regrowth. However, with both small and large tumours, the growth rate of residual tumour cells was inhibited by MTP, as evidenced by smaller tumours than in excised controls.
In Exp. 3 (Table) , in which the time course of tumour recurrence was determined, the effect of MTP was quite evident as a slow onset of tumour appearance, small tumour and prolonged survival (not shown). However, since all the animals finally died of cancer, it was indicated that MTP-potentiated host defences were finite, and could be overpowered by the growing tumour.
When the same experiments were repeated with a slightly more immunogenic Cl2TSV5S tumour, the results were more encouraging. MTP-mediated host defences were not overcome by residual tumour, and in only one experiment was there tumour recurrence. This promising observation could have been aided by the slower growth of this tumour and/or the insufficient number of cells left behind after surgery, since 40% of the excised controls also formed no local tumours.
We were also able to show that, in the case of Cl2TSV5S tumour, challenge of 106 tumour cells in animals with no apparent recurrent tumours (untreated or MTPtreated), tumours grew at the challenge site in 75% of the animals excised of their tumours, whereas the tumour takes were lower (25-43%) in post-or pre-and postoperatively MTP-treated animals.
Our observation that pre-and postoperative MTP appeared to be superior to postoperative MTP alone can only be commented upon briefly. Such observations require extensive confirmatory studies, with many animals in this and other tumour systems, to generalize from our observations, since the differences have poor significance. Such studies would be important, insofar as they could suggest the timings of immunotherapeutic manoeuvres, for tumour-bearers who are to undergo tumour surgery.
